Gyre Therapeutics Income Statement (2010-2026) | GYRE

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	1.13M	2.30M	2.44M	0.79M			101.50M	24.93M	29.33M	32.04M	27.15M	27.17M	25.23M	25.49M	27.87M	22.06M	26.77M	30.56M	37.20M	22.52M
Cost of Revenue (Quarter)	1.14M	2.31M	2.45M	0.80M			4.00M	1.12M	1.08M	13.93M	57.77M	0.98M	0.77M	0.96M	1.18M	0.89M	15.19M	1.63M	23.82M	14.14M
Gross Profit (Quarter)	-0.01M	-0.01M	-0.01M	-0.00M			97.50M	23.81M	28.25M	30.86M	25.90M	26.19M	24.45M	24.53M	26.70M	21.16M	25.62M	28.94M	13.38M	8.38M
Operating items
Research & Development (Quarter)	15.39M	20.35M	-50.15M	9.70M	1.87M	0.80M	4.31M	2.63M	3.57M	3.01M	4.57M	2.18M	3.35M	2.77M	3.71M	3.10M	3.42M	2.36M	4.82M	6.74M
Selling, General & Administrative (Quarter)	4.52M	4.87M	4.16M	4.99M	3.84M	4.36M	4.17M	1.74M	1.71M	1.16M	10.05M	3.40M	3.42M	3.82M	5.46M	4.96M	4.83M	4.32M	6.70M	7.22M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)	1.14M	2.31M	68.74M	0.80M	57.24M		-0.06M	4.74M		-0.53M	-2.17M	12.54M	-0.07M		0.00M	10.84M	-0.00M	-0.00M	-0.00M	17.92M
Operating Expenses (Quarter)	21.05M	27.53M	22.75M	15.49M	-51.53M	5.17M	123.96M	17.14M	23.28M	18.09M	122.17M	18.12M	22.03M	20.30M	27.21M	18.89M	23.45M	23.64M	40.75M	31.87M
Operating Income (Quarter)	-19.91M	-25.23M	-20.31M	-14.70M	51.53M	-5.17M	-22.46M	6.66M	4.97M	12.76M	-91.63M	8.07M	3.19M	4.23M	0.67M	2.27M	2.17M	6.92M	-8.34M	-9.36M
EBIT (Quarter)	-19.91M	-25.23M	-20.31M	-14.70M	51.53M	-5.17M	-22.46M	6.66M	4.97M	12.76M	-91.63M	8.07M	3.19M	4.23M	0.67M	2.27M	2.17M	6.92M	-8.34M	-9.36M
Non-operating items
Interest & Investment Income (Quarter)	0.01M	0.01M	-0.07M	0.17M	0.10M	0.28M	0.17M	0.10M	0.07M	0.05M
Other Non Operating Income (Quarter)	-0.03M	-0.02M	-0.02M	-0.02M	0.02M	-0.00M	0.86M	0.07M	0.63M	-1.33M	-0.24M	0.12M	-0.07M	-0.07M	-1.63M	0.11M	-0.14M	0.73M	-2.19M	0.03M
Non Operating Income (Quarter)	-0.03M	-0.02M	-0.02M	-0.02M	0.02M	-0.00M			0.63M	-1.33M	-0.24M	0.12M	-0.07M	-0.07M	-1.63M	0.11M	-0.14M	0.73M	-2.19M	0.03M
Net income details
EBT (Quarter)	-19.90M	-25.22M	-20.39M	-14.54M	51.63M	-4.88M	-22.80M	6.27M	5.85M	11.19M	-100.28M	12.48M	6.04M	3.93M	-0.43M	4.63M	2.24M	7.63M	-19.69M	-9.24M
Tax Provisions (Quarter)							5.10M	2.05M	2.08M	3.68M	0.70M	2.55M	1.50M	1.07M	1.21M	0.90M	0.66M	1.69M	2.41M	0.62M
Profit After Tax (Quarter)	-19.93M	-25.24M	-20.33M	-14.54M	51.63M	-4.88M	-27.90M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	0.57M	3.73M	1.58M	5.94M	-1.32M	-9.86M
Income from Non-Controlling Interests (Quarter)								1.97M	1.92M	3.53M	0.03M	2.40M	1.01M	1.73M	0.67M	1.04M	1.13M	2.33M	0.36M	-1.17M
Income from Continuing Operations (Quarter)	-19.90M	-25.22M	-20.39M	-14.54M	51.63M	-4.88M	-27.90M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	-1.64M	3.73M	1.58M	5.94M	-22.10M	-9.86M
Consolidated Net Income (Quarter)	-19.90M	-25.22M	-20.39M	-14.54M	51.63M	-4.88M	-27.90M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	-1.64M	3.73M	1.58M	5.94M	-22.10M	-9.86M
Income towards Parent Company (Quarter)	-19.90M	-25.22M	-20.39M	-14.54M	51.63M	-4.88M	-27.90M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	-1.64M	3.73M	1.58M	5.94M	-22.10M	-9.86M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-19.93M	-25.24M	-20.39M	-14.54M	51.63M	-4.88M	-29.91M	2.24M	1.85M	3.98M	-101.01M	7.53M	3.53M	1.12M	-0.10M	2.70M	0.44M	3.61M	-1.72M	-8.69M
Additional items
EPS (Basic) (Quarter)	-0.64	-0.80	-0.64	-0.46	1.64	-0.16	-1.28	0.04	0.03	0.06	-1.54	0.09	0.04	0.01	0.00	0.03	0.00	0.04	-0.02	-0.10
EPS (Weighted Average and Diluted) (Quarter)	-0.64	-0.80	-0.64	-0.46	1.64	-0.16	-1.28	0.03	0.02	0.05	-1.51	0.03	0.01	0.01				0.03	-0.02	-0.10
Shares Outstanding (Weighted Average) (Quarter)	29.88M	30.38M	30.64M	31.46M	31.48M	31.47M	63.59M	63.59M	37.78M	63.59M	65.83M	83.27M	85.50M	84.81M	85.09M	86.42M	89.12M	88.71M	89.34M	91.32M
Shares Outstanding (Diluted Average) (Quarter)	29.88M	30.38M	30.64M	31.46M	31.47M	31.48M	31.55M	37.98M	37.78M	37.98M
EBITDA (Quarter)	-19.91M	-25.23M	-20.31M	-14.70M	51.53M	-5.17M	-22.46M	6.66M	4.97M	12.76M	-91.63M	8.07M	3.19M	4.23M	0.67M	2.27M	2.17M	6.92M	-8.34M	-9.36M
Interest Expenses (Quarter)								0.64M				0.32M
Tax Rate (Quarter)							-22.36%	32.75%	35.60%	32.87%	-0.70%	20.40%	24.81%	27.33%	-277.01%	19.44%	29.58%	22.19%	-12.23%	-6.72%

Research Tools

Gyre Therapeutics Income Statement (2010-2026) | GYRE

Create an account

Sign In

Reset Password